Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL29662377

C/C(=C\COP(=O)(O)OP(=O)(O)O)CC/C=C(\C)CNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21.N.N.N

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLCD1 P51178 1/20 0.50
▸ TDP1 Q9NUW8 5/20 0.48
▸ F2 P00734 1/20 0.48
▸ PRSS1 P07477 1/20 0.48
▸ PRSS2 P07478 1/20 0.48
▸ PRSS3 P35030 1/20 0.48
▸ TPSAB1 Q15661 1/20 0.48
▸ MEN1 O00255 1/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ IDE P14735 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ RIN1 Q13671 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ FNTA P49354 3/20 0.43
▸ PGGT1B P53609 2/20 0.43
▸ FNTB P49356 1/20 0.43
▸ CA12 O43570 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19350969 0.99 PLCD1 (0.51) PLCD1TDP1F2PRSS1PRSS2
SCHEMBL19350968 0.89 TDP1 (0.48) PLCD1TDP1F2PRSS1PRSS2
Geranyl Diphosphate SCHEMBL19329153 0.86 TDP1 (0.56) PLCD1TDP1MEN1ABL1LMNA
SCHEMBL20656160 0.83 TDP1 (0.55) TDP1F2PRSS1PRSS2PRSS3
SCHEMBL22600908 0.82 HLCS (0.59) TDP1F2PRSS1PRSS2PRSS3
SCHEMBL19350967 0.80 TDP1 (0.47) PLCD1TDP1F2PRSS1PRSS2
SCHEMBL12672576 0.76 TDP1 (0.63) TDP1F2PRSS1PRSS2PRSS3
SCHEMBL13110899 0.75 TDP1 (0.67) TDP1F2PRSS1PRSS2PRSS3
Biotin SCHEMBL7845644 0.73 TDP1 (0.77) PLCD1TDP1F2PRSS1PRSS2
SCHEMBL20306213 0.73 PLCD1 (0.65) PLCD1TDP1F2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109072281-B Prenylation assay 夜星有限公司 2023-07-25 — — CN claimed
EP-3429569-B1 METHODS FOR PREVENTING OR TREATING PARKINSON'S DISEASE BY THE FARNESYLATION OF PARIS UNIV JOHNS HOPKINS (US) 2025-05-28 — — EP disclosed
CN-109072281-B Prenylation assay 夜星有限公司 2023-07-25 — — CN disclosed
US-20230012209-A1 METHODS OF PREVENTING OR TREATING PARKINSON'S DISEASE BY THE FARNESYLATION OF PARIS THE JOHNS HOPKINS UNIVERSITY 2023-01-12 — — US disclosed
WO-2022109247-A1 VIRAL VECTOR POTENCY ASSAY BIOGEN MA INC. (US) 2022-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230012209-A1 METHODS OF PREVENTING OR TREATING PARKINSON'S DISEASE BY THE FARNESYLATION OF PARIS PINK1, PGC, SNCA PLCD1 3641/4885TDP1 1926/4885F2 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback